Ribavirin, a broad-spectrum antiviral agent, has been recom-mended
for the aerosolized treatment of children with severe RSV disease. This has
shown beneficial effect by decreasing the duration of illness and decreasing
the shedding of viruses in respiratory secretions.
Prevention and Control
Passive immunization with anti-RSV immunoglobulin has proved
beneficial for use for prophylaxis in high-risk infants such as premature
babies or babies with chronic lung dis-ease. The anti-RSV immunoglobulin is a
pooled polyclonal human immunoglobulin product with high titers of RSV
Attempts to use a vaccine against RSV have been proved unsuccessful
to date. Previously, a formalin-inactivated RSV vaccine was used in children,
but the children who received this vaccine developed more severe disease than
those who were exposed to natural RSV infection; hence, this vaccine is no
lon-ger used. Recently, a live attenuated RSV vaccine that can be used as nasal
spray is under evaluation.